Liza R. Gibbs

Liza R. Gibbs

Auto-generated profile, based on publicly available information

Liza R. Gibbs

Aetion Inc, New York, NY, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2023 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
SHSari Hopson
Sari Hopson
LGLiza R. Gibbs
Liza R. Gibbs
SSSahar Syed
Sahar Syed
RLRobert Low
Robert Low
LMLaura McClung
Laura McClung
SBSilky Beaty
Silky Beaty
Introduction Psoriasis (PSO), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), and hidradenitis suppurativa (HS) are chronic inflammatory diseases (CIDs) often diagnosed and treated individually. However, genetic overlaps exist among CIDs, and patients with one are at risk of developing others within the same spectrum. This analysis characterized treatment patterns along with clinical and economic burdens of newly diagnosed CIDs among patients with an additional past diagnosis of PSO, PsA, axSpA, or HS. Methods This study used MarketScan® databases to examine demographics, treatment patterns, and healthcare resource utilization for patients with ≥ 1 claim for PSO or HS or ≥ 2 claims for PsA or axSpA, and continuous enrollment in the year before (baseline period) and following (follow-up period) the date of first diagnosis (incident diagnosis). Comorbidities and new CID diagnoses with a past diagnosis of PSO, PsA, axSpA, or HS, were examined. Results The analysis included 298,794 patients (maximum of 1202 patients with ≥ 1 incident diagnoses): 134,233 had incident PSO; 9914 had incident PsA; 115,194 had incident axSpA; and 40,655 had incident HS. Prevalence of ≥ 1 CID diagnosis among patients with past diagnosis of PSO, PsA, axSpA, or HS was 4959/134,233 (3.7%), 5256/9914 (53.0%), 3205/115,194 (2.8%), and 1180/40,655 (2.9%), respectively. In patients with incident axSpA and past PsA diagnosis, incident axSpA and past HS diagnosis, and incident HS and past PSO diagnosis, steroid and opioid use were high across baseline and follow-up periods and use of biologic disease-modifying antirheumatic drugs increased from baseline to follow-up. Disease-related costs increased absolutely and increased or remained high as a proportion of all-cause costs. Conclusion Patients with newly diagnosed CIDs and additional past diagnosis of PSO, PsA, axSpA, or HS experienced high treatment utilization and healthcare costs. These findings highlight the need for payers, health technology assessment agencies, clinicians, and other stakeholders to explore the co-management of CIDs, rather than treating them separately.

21 October 2025 in Tremor and Other Hyperkinetic Movements
Verified
Journal Article
Open access
PDF file
JLJunji Lin
Junji Lin
RPRajesh Pahwa
Rajesh Pahwa
ELElan D. D Louis
Elan D. D Louis
RSRagy Saad
Ragy Saad
KLKelly E. Lyons
Kelly E. Lyons
SSSanket Shah
Sanket Shah
Background: Essential tremor (ET) is one of the most common movement disorders. Previous estimates of ET prevalence vary due to multiple factors. This study estimated the prevalence of diagnosed ET. Methods: The prevalence of diagnosed ET was estimated among adults with continuous enrollment in 2022 and ≥1 additional year of prior baseline enrollment in the Merative™ MarketScan® Research Databases, a US administrative claims database. ET was defined as ≥2 ET claims within 12 months of one another during the 2016–2022 study period. The proportion of patients receiving treatment was defined as having a claim for possible medication for ET in 2022 among those with diagnosed ET who had an additional 6 months of follow-up following the first ET diagnosis claim. Age-standardized estimates of the number of US adults with diagnosed ET were calculated using 2024 US population census projections. Results: The prevalence of diagnosed ET was 0.28% before age standardization, ranging from 0.06% (18–40 years) to 1.61% (≥75 years); 74% of patients overall received possible treatment. After standardization, prevalence was 0.42%; in 2024, 1.1 million US adults were estimated to have diagnosed ET. Estimates of the prevalence of diagnosed ET in the US were susceptible to the choice of case definition, nearly doubling (ie, 2.1 million US adults) with a more sensitive definition. Discussion: ET affects a substantial proportion of the US adult population. Selecting appropriate case definitions and using methods such as standardization are critical for estimating valid and generalizable chronic condition prevalences with real-world data. Highlights This study found that 1.1 million US adults were estimated to have been diagnosed with essential tremor, with the sensitivity analyses yielding additional estimates. Estimating reliable and generalizable prevalences of diagnosed chronic conditions requires selection of appropriate case definitions and standardization to the general population.

1 December 2021 in Contraception
Verified
Journal Article
Closed access
LGLiza R. Gibbs
Liza R. Gibbs
JPJulia A. Pisc
Julia A. Pisc
KBKari P. Braaten
Kari P. Braaten
BBBrian T. Bateman
Brian T. Bateman
EGElizabeth M Garry
Elizabeth M Garry

25 September 2023 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
LGLiza R. Gibbs
Liza R. Gibbs
AAAyad K. Ali
Ayad K. Ali
DADawn G. Albright
Dawn G. Albright
EREmily R. Rubinstein
Emily R. Rubinstein
RKReyna Klesh
Reyna Klesh
EGElizabeth M Garry
Elizabeth M Garry

11 September 2023
Verified
Preprint
Open access
PDF file
LRLiza Gibbs R
Liza Gibbs R
AKAyad Ali K
Ayad Ali K
DADawn Albright
Dawn Albright
EREmily Rubinstein R
Emily Rubinstein R
RKReyna Klesh
Reyna Klesh
EGElizabeth M Garry
Elizabeth M Garry
A document by Liza Gibbs R. Click on the document to view its contents.

13 January 2025 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
AAAyad K. Ali
Ayad K. Ali
ABAidan Baglivo
Aidan Baglivo
PGPriya Govil
Priya Govil
LGLiza R. Gibbs
Liza R. Gibbs
MBMarie C. Bradley
Marie C. Bradley
EGElizabeth M Garry
Elizabeth M Garry